Pharmaceutical preparations for the treatment and prevention of chronic obstructive pulmonary disease, pulmonary arterial hypertension, acute liver failure, acute-on-chronic liver failure, liver fibrosis, metabolic dysfunction associated fatty liver disease, nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, lung fibrosis, organ fibrosis, and inflammatory diseases; each of the foregoing excluding those featuring oral vaporizers for smoking purposes and oral vaporizers for smokers

'acut':16,20 'acute-on-chron':19 'arteri':14 'associ':29 'chronic':9,22 'diseas':12,32,44 'dysfunct':28 'exclud':49 'failur':18,24 'fatti':30 'featur':51 'fibrosi':26,37,39,41 'forego':48 'hypertens':15 'idiopath':35 'inflammatori':43 'liver':17,23,25,31 'lung':38 'metabol':27 'nonalcohol':33 'obstruct':10 'oral':52,58 'organ':40 'pharmaceut':1 'prepar':2 'prevent':7 'pulmonari':11,13,36 'purpos':56 'smoke':55 'smoker':61 'steatohepat':34 'treatment':5 'vapor':53,59

Conducting early evaluations in the field of new pharmaceuticals; Pharmaceutical products development; Research and development in the pharmaceutical and biotechnology fields; Testing of pharmaceuticals; each of the foregoing excluding those featuring oral vaporizers for smoking purposes and oral vaporizers for smokers

'biotechnolog':20 'conduct':1 'develop':12,15 'earli':2 'evalu':3 'exclud':29 'featur':31 'field':6,21 'forego':28 'new':8 'oral':32,38 'pharmaceut':9,10,18,24 'product':11 'purpos':36 'research':13 'smoke':35 'smoker':41 'test':22 'vapor':33,39

GYRE

Owner

Goods & Services